FindTrial
Sign In

Smac Mimetic LCL161

DRUG2 trials

Sponsors

Mayo Clinic, M.D. Anderson Cancer Center

Conditions

Polycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary MyelofibrosisRecurrent Plasma Cell MyelomaRefractory Plasma Cell MyelomaSecondary Myelofibrosis

Phase 2

SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
CompletedNCT01955434
Mayo ClinicRecurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Start: 2013-11-30End: 2016-12-27Updated: 2019-09-10
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
CompletedNCT02098161
M.D. Anderson Cancer CenterPolycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis
Start: 2014-12-18End: 2022-05-19Updated: 2023-06-06

Related Papers

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis
Blood Advances2021-08-2032 citations
Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
Blood2019-11-1319 citations
LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial
Blood2018-11-2923 citations
Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis
Blood2017-12-075 citations
Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF)
Blood2016-12-0216 citations